Dimon noted that the full impact of Trump’s tariffs on the economy is not apparent yet, even as some analysts expressed optimism about the outlook for U.S. equities.
U.S. stocks trimmed early-session losses by midday Monday, as investors showed limited concern after Moody's downgraded U.S. sovereign credit from Aaa to Aa1, effectively stripping the world's largest economy of its last top-tier credit rating.
According to Dalio, Moody’s downgrade only focuses on the government’s capacity to repay its debt, not the risk of its being able to print more money to repay that debt.
Morgan Stanley’s Wilson noted that the corporate earnings season has shown no major impact due to Trump’s tariffs, and a slew of recent profit upgrades is another green sign.
Jeremy Barnum also said that the combination of inflation and large fiscal deficits may constrain the available policy responses in ways that further increase the risk.
Moody's downgraded US credit rating from Aaa to Aa1, triggering concerns of a 10% market correction. But history has shown dips are buying opportunities.
Investors have grown cautious of retail businesses in an environment marked by an uncertain tariff policy, high inflation, and unpredictable consumer behavior.
Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
Shares of the company plunged more than 23% last week, hitting a new five-year low on Thursday after a Wall Street Journal report that the DoJ is conducting a criminal probe into potential Medicare fraud.
The advance first-quarter GDP estimate released late April showed that the economy contracted at a 0.3% rate, with the weakness stemming primarily from an increase in imports.
